The serotonin transporter gene and effectiveness of SSRIs

Expert Review of Neurotherapeutics

Volumn 8, Issue 1, 2008, Pages 111-120

  Serretti, Alessandro ^a   Kato, Masaki ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

5 HTTLPR; Depression; Mood disorder; Pharmacogenetics; Polymorphism; SERTPR; SSRI; Treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; GENE SEQUENCE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; META ANALYSIS; MOOD DISORDER; NAUSEA; PATHOGENESIS; PROMOTER REGION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; HUMANS; MOOD DISORDERS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 38149049267     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.1.111     Document Type: Review

References (108)

1. Bauwens F, Tracj A, Pardoen D, Vander Elst M, Mendlewicz J. Social adjustment of remitted bipolar and unipolar out-patients. A comparison with age- and sex-matched controls. Br. J. Psychiatry 159, 239-244 (1991).
2. Pincus HA, Pettit AR. The societal costs of chronic major depression. J. Clin. Psychiatry 62(Suppl. 6), 5-9 (2001).
3. Rice DP. The economic impact of schizophrenia. J. Clin. Psychiatry 60(Suppl. 1), 4-6; discussion 28-30 (1999).
4. Grunze H, Kasper S, Goodwin G et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J. Biol. Psychiatry 3(3), 115-124 (2002).
5. Geddes JR, Freemantle N, Mason J et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst. Rev. 2, CD001851 (2000).
6. Goodnick PJ. Predictors of tReatment Response In Mood Disorders. Clinical Practice. American Psychiatric Press, Washington, DC, USA (1996).
7. Esposito K, Goodnick P. Predictors of response in depression. Psychiatr. Clin. North Am. 26(2), 353-365 (2003).
8. Nierenberg AA. Predictors of response to antidepressants general principals and clinical implications. Psychiatr. Clin. North Am. 26, 345-352 (2003).
9. Orsini A. Antidepressant responses and segregation analyses in affective families. In: Anxious Depression: Assessment and Treatment. Racagni G, Smeraldi E (Eds). Raven Press, NY, USA (1987).
10. Sederer LI. Depression. In: Inpatients Psychiatry Diagnosis and Treatment. Sederer LI (Ed). William & Wilkins, MD, USA (1986).
11. Berrettini W. Progress and pitfalls: bipolar molecular linkage studies. J. Affect. Disord. 50(2-3), 287-297 (1998).
12. Pare CM, Mack JW. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J. Med. Genet. 8(3), 306-309 (1971).
13. Serretti A, Artioli P, Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet. Genomics 15(2), 61-67 (2005). •• Comprehensive review of pharmacogenetics in affective disorder.
14. Jacobs BL, Fornal CA. Serotonin and behavior. A general hypothesis. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds). Raven Press, NY, USA 461-469 (1995).
15. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds). Raven Press, NY, USA. 933-944 (1995).
16. Holmes A, Murphy DL, Crawley JN. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol. Psychiatry 54(10), 953-959 (2003).
17. 1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28(12), 2077-2088 (2003).
18. Ramamoorthy S, Bauman AL, Moore KR et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl Acad. Sci. USA 90(6), 2542-2546 (1993).
19. Lesch KP, Balling U, Gross J et al. Organization of the human serotonin transporter gene. J. Neural. Transm. Gen. Sect. 95(2), 157-162 (1994). •• First report of the functional efficacy of the serotonin transporter (SERTPR).
20. Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66(6), 2621-2624 (1996).
21. Eichhammer P, Langguth B, Wiegand R et al. Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). Psychopharmacology (Berl.) 166(3), 294-297 (2003).
22. Smeraldi E, Zanardi R, Benedetti F et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3(6), 508-511 (1998).
23. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J. Clin. Psychopharmacol. 20(1), 105-107 (2000).
24. Pollock BG, Ferrell RE, Mulsant BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23(5), 587-590 (2000).
25. Zanardi R, Rossini D, Serretti A. Problems with ensuring double blind - replay. J. Clin. Psychiatry 62(4), 296 (2001).
26. Rausch JL, Johnson ME, Fei Y-J et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol. Psychiatry 51(9), 723-732 (2002).
27. Arias B, Catalan R, Gasto C et al. Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram. In: World Federation of Societies of Biological Psychiatry. The World Journal of Biological Psychiatry, Berlin, Germany 9S (2001).
28. Joyce PR, Mulder RT, Luty SE et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol. 6(4), 339-346 (2003).
29. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 61(11), 1163-1169 (2004).
30. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl.) 174(4), 525-529 (2004).
31. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry 7(10), 1115-1119 (2002). •• First report identifying specific SERTPR symptoms effects.
32. Lee MS, Lee HY, Lee HJ, Ryu SH. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr. Genet. 14(2), 111-115 (2004).
33. Kato M, Ikenaga Y, Wakeno M et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int. Clin. Psychopharmacol. 20(3), 151-156 (2005). •• First report comparing the clinical response of two selective serotonin reuptake inhibitors (SSRIs) considering SERTPR.
34. Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53(4), 186-195 (2006).
35. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 6(1), 27-33 (2006).
36. Kim DK, Lim SW, Lee S et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11(1), 215-219 (2000).
37. Yoshida K, Ito K, Sato K et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 26(2), 383-386 (2002).
38. Kim H, Lim S-W, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 296(13), 1609-1618 (2006).
39. Ng CH, Easteal S, Tan S et al. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(5), 953-957 (2006).
40. Serretti A, Mandelli L, Lorenzi C et al. Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res. 149(1-3), 185-193 (2007). •• First report identifying specific SERTPR symptoms effects in Caucasian.
41. Kraft JB, Peters EJ, Slager SL et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol. Psychiatry 61(6), 734-742 (2006). •• Largest SERTPR study not confirming association with response.
42. Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am. 26(2), 457-494 (2003).
43. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. (2007) (Epub ahead of print). •• Methodological guidelines for future pharmacogenetic study.
44. Hu XZ, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64(7), 783-792 (2007).
45. Perlis R, Smoller J, Wan Y et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. In: Pharmacogenetics in Psychiatry Meeting. Hospital, TZH, NY, USA (2003).
46. Takahashi H, Yoshida K, Ito K et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur. Neuropsychopharmacol. 12(5), 477-481 (2002).
47. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch. Gen. Psychiatry 58, 539-544 (2001).
48. Masoliver E, Menoyo A, Perez V et al. Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr. Genet. 16(1), 25-29 (2006).
49. Rousseva A, Henry C, Van Den Bulke D et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J. 3(2), 101-104 (2003).
50. Serretti A, Artioli P, Zanardi R et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl.) 174(4), 504-511 (2004).
51. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 12(3), 247-257 (2007). •• First meta-analysis of SERTPR association with SSRIs.
52. Lesch KP. Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur. Neuropsychopharmacol. 11(6), 457-474 (2001).
53. Hranilovic D, Stefulj J, Schwab S et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol. Psychiatry 55(11), 1090-1094 (2004).
54. Greenberg BD, Tolliver TJ, Huang SJ et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 88(1), 83-87 (1999).
55. Javors MA, Seneviratne C, Roache JD et al. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(1), 7-13 (2005).
56. Teshima KM, Przeworski M. Directional positive selection on an allele of arbitrary dominance. Genetics 172(1), 713-718 (2006).
57. Williams NM, O'Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr. Bull. 31(4), 800-805 (2005).
58. Allison DB, Thiel B, Stjean P et al. Multiple phenotype modeling in gene-mapping studies of quantitative traits - power advantages. Am. J. Hum. Genet. 63(4), 1190-1201 (1998).
59. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry 5(1), 32-38 (2000).
60. Smeraldi E, Serretti A, Artioli P, Lorenzi C, Catalano M. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr. Genet. 16(4), 153-158 (2006).
61. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 9(9), 879-889 (2004).
62. Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol. Psychiatry 58(5), 374-381 (2005).
63. Hu XZ, Lipsky RH, Zhu G et al. Serotonin transporter promoter gain-offunction genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78(5), 815-826 (2006).
64. Kunugi H, Hattori M, Kato T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry 2(6), 457-462 (1997).
65. Serretti A, Zanardi R, Rossini D et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry 6, 586-592 (2001).
66. Kendler KS. "A gene for" the nature of gene action in psychiatric disorders. Am. J. Psychiatry 162(7), 1243-1252 (2005).
67. Serretti A, Calati R, Mandelli L, De Ronchi D. Serotonin transporter gene variants and behaviour: a comprehensive review. Curr. Drug Targets 7, 1659-1669 (2006).
68. Veenstra-VanderWeele J, Anderson GM, Cook EH. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur. J. Pharmacol. 410(2-3), 165-181 (2000).
69. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am. J. Psychiatry 158(8), 1265-1270 (2001).
70. Rice JP, Rochberg N, Endicott J, Lavori PW, Miller C. Stability of psychiatric diagnoses. An application to the affective disorders. Arch. Gen. Psychiatry 49(10), 824-830 (1992).
71. Tsuang M, Faraone S. The Genetics of Mood Disorders. The Johns Hopkins University Press, MD, USA (1990).
72. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am. J. Psychiatry 159(3), 469-473 (2002).
73. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 9(9), 879-889 (2004).
74. Mitchell AJ. Two-week delay in onset of action of antidepressants: new evidence. Br. J. Psychiatry 188, 105-106 (2006).
75. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J. Clin. Psychiatry 66(2), 159-166; quiz 147, 273-154 (2005).
76. Meyers BS, Sirey JA, Bruce M et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch. Gen. Psychiatry 59(8), 729-735 (2002).
77. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am. J. Psychiatry 157(Suppl. 4), 1-45 (2000).
78. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 3(1), 5-43 (2002).
79. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr. Scand. 101(5), 354-359 (2000).
80. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur. Arch. Psychiatry Clin. Neurosci. 255(6), 387-400 (2005).
81. Lotrich FE, Bies RR, Smith GS, Pollock BG. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J. Psychopharmacol. 20(Suppl. 4), 33-40 (2006).
82. Serretti A, Cusin C, Benedetti F et al. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 137(1), 36-39 (2005).
83. Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292), 1527-1531 (1996).
84. Melke J, Landen M, Baghei F et al. Serotonin transporter gene polymorphisms are associated with anxiety-related personality traits in women. Am J. Med. Genet. 105(5), 458-463 (2001).
85. Bailey DS, Bondar A, Furness LM. Pharmacogenomics - it's not just pharmacogenetics. Curr. Opin. Biotechnol. 9(6), 595-601 (1998).
86. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21(Suppl. 1), 33-37 (1999).
87. Kao CM. Functional genomic technologies: creating new paradigms for fundamental and applied biology. Biotechnol. Prog. 15(3), 304-311 (1999).
88. Chen B, Wang JF, Sun X, Young LT. Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. Biol. Psychiatry 53(6), 530-537 (2003).
89. Drigues N, Poltyrev T, Bejar C, Weinstock M, Youdim MB. cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs. J. Neural Transm. 110(12), 1413-1436 (2003).
90. Landgrebe J, Welzl G, Metz T et al. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J. Psychiatr Res. 36(3), 119-129 (2002).
91. Yamada M, Yamada M, Higuchi T. Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(6), 999-1009 (2005).
92. Palotas A, Puskas LG, Kitajka K et al. The effect of citalopram on gene expression profile of Alzheimer lymphocytes. Neurochem. Res. 29(8), 1563-1570 (2004).
93. Lachman HM, Kelsoe JR, Remick RA et al. Linkage studies suggest a possible locus for bipolar disorder near the velo-cardio-facial syndrome region on chromosome 22. Am. J. Med. Genet. 74, 121-128 (1997).
94. Niculescu AB III, Segal DS, Kuczenski R et al. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol. Genomics 4(1), 83-91 (2000).
95. Alda M. Pharmacogenetics of lithium response in bipolar disorder. J. Psychiatry Neurosci. 24(2), 154-158 (1999).
96. Bellivier F, Leroux M, Henry C et al. Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neurosci. Lett. 334(1), 17-20 (2002).
97. Nobile M, Cataldo MG, Giorda R et al. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol. Psychiatry 56(4), 292-295 (2004).
98. Cusin C, Serretti A, Lattuada E et al. Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. J. Psychiatric Res. 35(4), 217-223 (2001).
99. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631), 386-389 (2003).
100. Park JW, Kim JS, Lee HK, Kim YI, Lee KS. Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. Headache 44(10), 1005-1009 (2004).
101. Feinn R, Nellissery M, Kranzler HR. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 133(1), 79-84 (2005).
102. Kremer I, Bachner-Melman R, Reshef A et al. Association of the serotonin transporter gene with smoking behavior. Am. J. Psychiatry 162(5), 924-930 (2005).
103. Yeo A, Boyd P, Lumsden S et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 53(10), 1452-1458 (2004).
104. Matsushita S, Suzuki K, Murayama M et al. Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 128(1), 114-117 (2004).
105. Steiger H, Joober R, Israel M et al. The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int. J. Eat. Disord. 37(1), 57-60 (2005).
106. Courtet P, Baud P, Abbar M et al. Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene. Mol. Psychiatry 6(3), 338-341 (2001).
107. Bartlett CW, Gharani N, Millonig JH, Brzustowicz LM. Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. Int. J. Dev. Neurosci. 23(2-3), 221-234 (2005).
108. Bobb AJ, Castellanos FX, Addington AM, Rapoport JL. Molecular genetic studies of ADHD: 1991 to 2004. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 132(1), 109-125 (2005).